Skip to main content
ADIL logo

Adial Pharmaceuticals, Inc.

ADILNASDAQHealthcareBiotechnology

$3.49Today:- (-)1Y +772.46%

As of Oct 16, 2026 close

Market cap
$14.51M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.32$8.75
Volume (live)
-
Avg. volume (3M)
44.87K

Adial Pharmaceuticals (ADIL) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Adial Pharmaceuticals used $6.49M of cash in operating activities and spent $3.00 on capital expenditures. That left free cash flow of −$6.49M.

Adial Pharmaceuticals Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Adial Pharmaceuticals, Inc. (ADIL) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Mar 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-7.98-13.20-7.00-7.00-10.80-19.42-10.89-8.59-11.63-1.14
Depreciation & Amortization0.000.000.000.000.000.060.000.000.000.00
Deferred Income Tax0.000.000.00-0.00-0.09-1.560.003.480.00
Stock Based Compensation0.680.801.751.753.374.242.011.605.370.21
Change in Working Capital0.470.39-0.79-0.79-1.171.461.250.21-0.850.34
Change in Accounts Receivable0.000.000.00-0.000.000.000.000.000.00
Change in Accounts Payable0.360.17-0.16-0.160.02-0.350.620.09-0.030.32
Change in Other Working Capital-0.150.06-0.630.050.050.280.620.12-0.810.01
Other Operating Activities-0.155.09-0.760.051.940.281.560.441.130.10
Net Cash from Operating Activities-6.49-6.92-6.81-6.81-11.19-11.95-7.63-6.34-2.50-0.49
Investing Activities
Capital Expenditures0.000.006.81-0.00-0.060.000.000.000.00
Acquisitions0.000.000.00-0.000.030.000.000.000.00
Other Investing Activities0.150.001.50-0.000.00-0.350.000.000.04
Net Cash from Investing Activities0.150.001.501.500.00-0.03-0.350.000.000.04
Financing Activities
Debt Repayment0.000.000.00-0.000.000.000.00-0.080.35
Common Stock Issued3.667.854.130.759.1311.756.178.206.270.04
Common Stock Repurchased0.000.000.000.000.000.000.000.000.000.00
Other Financing Activities0.003.820.000.000.001.89-0.561.050.160.00
Net Cash from Financing Activities8.477.854.134.139.1313.645.619.256.350.39
Summary
Net Change in Cash2.130.92-1.17-1.17-2.061.66-2.382.913.85-0.07
Cash at Beginning of Period3.752.834.004.006.064.406.783.870.020.09
Cash at End of Period5.883.752.832.834.006.064.406.783.870.02
Free Cash Flow-6.49-6.920.00-6.81-11.19-12.01-7.63-6.34-2.50-0.49

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Adial Pharmaceuticals Cash Flow

What is Adial Pharmaceuticals's free cash flow?

Adial Pharmaceuticals had negative free cash flow of $6.49M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$6.49M minus $3.00 of capital expenditures.

How much does Adial Pharmaceuticals spend on capital expenditures?

Adial Pharmaceuticals spent $3.00 on capital expenditures in fiscal 2025.

Does Adial Pharmaceuticals pay dividends or buy back shares?

Adial Pharmaceuticals's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition